Detalhe da pesquisa
1.
AP-2γ Is Required for Maintenance of Multipotent Mammary Stem Cells.
Stem Cell Reports;
16(1): 106-119, 2021 01 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33382976
2.
AP-2α Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer.
Mol Cancer Res;
19(7): 1156-1167, 2021 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33753551
3.
A TFAP2C Gene Signature Is Predictive of Outcome in HER2-Positive Breast Cancer.
Mol Cancer Res;
18(1): 46-56, 2020 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31619506
4.
Comparative analysis of radioactive iodine versus thyroidectomy for definitive treatment of Graves disease.
Surgery;
161(1): 147-155, 2017 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27863789
5.
Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer.
Oncotarget;
8(70): 114801-114815, 2017 Dec 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29383121
6.
Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas.
Stem Cell Reports;
7(6): 1140-1151, 2016 12 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27916539
7.
EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.
Mol Cancer Ther;
15(3): 503-11, 2016 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26832794